Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Pan, Qi ^a   Yang, Guo Liang ^a   Yang, Jiang Hua ^a   Lin, Shi Long ^a   Liu, Ning ^b   Liu, Shan Shan ^b   Liu, Meng Yao ^b   Zhang, Lian Hua ^a   Huang, Yi Ran ^a   Shen, Ru Long ^c   Liu, Qiang ^a   Gao, Jian Xin ^a,b   Bo, Juan Jie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b School of Medicine   (China)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Bladder cancer; Cell cycle; Invasion; Metformin; Migration; Preneoplasm; Rat; Stat3

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; METFORMIN; METHYLNITROSOUREA; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLADDER PAPILLOMA; CANCER INHIBITION; CARCINOMA IN SITU; CONTROLLED STUDY; DYSPLASIA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR INVASION; ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; METFORMIN; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; URINARY BLADDER NEOPLASMS;

EID: 84940373656     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0183-0     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639-53.
3. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430-42.
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5. discussion 475-467.
5. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-74.
6. Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells. 2013;36(4):279-87.
7. Taubes G. Cancer research. Cancer prevention with a diabetes pill? Science. 2012;335:29.
8. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2:778-90.
9. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol. 2014;32(49):e47-14.
10. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int. 2013;112:1105-12.
11. Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013:421821.
12. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97-105.
13. Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012;72:3135-42.
14. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7:78.
15. Shahjee HM, Koch KR, Guo L, Zhang CO, Keay SK. Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res. 2010;29:160.
16. Correia S, Carvalho C, Santos MS, Seica R, Oliveira CR, Moreira PI et al. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem. 2008;8:1343-54.
17. Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci. 2013;14:24603-18.
18. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5:e1088.
19. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, et al. Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma. Clin Cancer Res. 2013;19:5372-80.
20. Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F, et al. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer. 2012;12:517.
21. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576-86.
22. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract. 2011;91:177-82.
23. Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int. 2007;100:1396-401.
24. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67:10804-12.
25. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269-73.
26. Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L, et al. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res. 2013;32:90.
27. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-7.
28. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD, et al. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 1997;75:1788-92.
29. Li H, Huang C, Huang K, Wu W, Jiang T, Cao J, et al. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One. 2011;6:e25941.
30. Qiu Z, Huang C, Sun J, Qiu W, Zhang J, Li H, et al. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci. 2007;98:1099-106.
31. Teng TS, Lin B, Manser E, Ng DC, Cao X. Stat3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIX. J Cell Sci. 2009;122:4150-9.
32. Debidda M, Wang L, Zang H, Poli V, Zheng Y. A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J Biol Chem. 2005;280:17275-85.
33. Steinberg GD, Brendler CB, Ichikawa T, Squire RA, Isaacs JT. Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res. 1990;50:6668-74.
34. Steinberg GD, Brendler CB, Squire RA, Isaacs JT. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model. J Urol. 1991;145:647-53.
35. Yaman O, Ozdiler E, Sozen S, Gogus O. Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model. Int J Urol. 1999;6:87-92.
36. Quaile MP, Melich DH, Jordan HL, Nold JB, Chism JP, Polli W, et al. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol. 2010;243:340-7.
37. Gao J-X. Development of Tumor Stem Cells: Implication in Field Cancerization. In: Dakubo G, editor. Field Cancerization: Basic Science and Clinical Applications. New York: Nova Science Publishers, Inc.; 2011. p. 26-69.
38. Gao JX. Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med. 2008;12:67-96.
39. Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, et al. Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. PLoS One. 2007;2:e293.
40. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX et al. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One. 2008;3:e1652.